| Literature DB >> 35889434 |
Christian Frabitore1, Jérome Lépeule1, Tom Livinghouse1.
Abstract
Nitrogen-containing heterocycles represent the majority of FDA-approved small-molecule pharmaceuticals. Herein, we describe a synthetic method to produce saturated N-heterocyclic drug scaffolds with an internal alkyne for elaboration. The treatment of N,N-dimethylhydrazinoalkenes with Et2Zn, followed by a Cu(I)-catalyzed cross-coupling with 1-bromoalkynes, results in piperidines and pyrrolidines with a good yield. Five examples are reported and a proposed mechanism for the Cu(I)-catalyzed cross-coupling is presented.Entities:
Keywords: catalysis; copper; cross-coupling; heterocycles
Mesh:
Substances:
Year: 2022 PMID: 35889434 PMCID: PMC9315687 DOI: 10.3390/molecules27144561
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Scheme 1Zn(II)-mediated metalloamination/cyclization with subsequent functionalization [9].
Figure 1Proposed mechanism for the Cu(I)-catalyzed cross-coupling of 1-bromoalkynes with alkyl zinc reagents [24].
Figure 2N,N-dimethylhydrazinoalkenes used in this study.
Results of the cross-coupling of 1-bromo-1-octyne and 1-bromo-2-phenylethyne with N,N-dimethylhydrazinoalkenes 1, 2, and 3.
| 1-Bromoalkyne | Product | Yield [%] |
|---|---|---|
|
|
| 77 b |
|
|
| 81 b
|
|
|
| 58 b |
|
|
| 66 b |
|
|
| 72 b |
a Product obtained as racemic mixture. b 0.1 mmol N,N-dimethylhydrazinoalkene, 5 mol% CuCN·2LiBr, and 1 equiv. LiBr. c 0.1 mmol N,N-dimethylhydrazinoalkene, 5 mol% CuCN·2LiBr, 1 equiv. LiBr, and 1 equiv. TMEDA. d 1.5 mmol N,N-dimethylhydrazinoalkene, 5 mol% CuCN·2LiBr, and 1 equiv. LiBr.